AZN logo

AstraZeneca (AZN) Return On Equity

Annual ROE

17.58%
+1.95%+12.48%

December 31, 2024

Summary

Performance

1-Year Change

+12.48%

3-Year Change

+4187.8%

5-Year Change

+88.63%

15-Year Change

-2.44%

AZN ROE Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

81.75%
AZN annual return on equity is higher than 81.75% of companies in Healthcare sector

High & Low

All-time High

80.71%
AZN annual return on equity is currently -78.22% below its historical high of 80.71%

3-Year Low

0.41%
AZN annual return on equity is currently +4187.80% above its 3-year low

Earnings dates

Last Annual Earnings Report Date

Dec 31, 2024
AZN previous annual earnings announcement was published on Dec 31, 2024

Next Annual Earnings Report Date

N/A
AZN next annual earnings announcement has not yet been scheduled

OtherAZNprofitabilitymetrics:

Annual Revenue

$54.07 B
AZN annual revenue is $54.07 billion

Annual Net Income

$7.04 B
AZN annual net profit is $7.04 billion

Annual EPS

$2.25
AZN annual earnings per share is $2.25

Annual ROA

6.86%
AZN annual return on assets is 6.86%

Quarterly ROE

17.77%
+1.06%+6.34%

December 31, 2024

Summary

Performance

3-Month Change

+6.34%

1-Year Change

+5.02%

3-Year Change

+573.87%

5-Year Change

+573.87%

AZN Quarterly ROE Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

82.23%
AZN quarterly return on equity is higher than 82.23% of companies in Healthcare sector

High & Low

All-time High

58.04%
AZN quarterly return on equity is currently -69.38% below its historical high of 58.04%

3-Year Low

-3.75%

Earnings dates

Last Quarterly Earnings Report Date

Dec 31, 2024
AZN previous earnings announcement was published on Dec 31, 2024

Next Quarterly Earnings Report Date

Apr 25, 2025
AZN next earnings announcement is scheduled for Apr 25, 2025

OtherAZNprofitabilitymetrics:

Quarterly Revenue

$14.89 B
AZN quarterly revenue is $14.89 billion

Quarterly Net Income

$1.50 B
AZN quarterly net profit is $1.50 billion

Quarterly EPS

$0.48
AZN quarterly earnings per share is $0.48

Quarterly ROA

6.81%
AZN quarterly return on assets is 6.81%

ROE Formula

ROE =  Net Income
Shareholders Equity ✕ 100%

Annual ROE

17.58%
AZN annual return on equity is 17.58%

Annual Net Income

$7.04 B
AZN annual net profit is $7.04 billion

Annual Shareholders Equity

$40.79 B
AZN annual stockholders equity is $40.79 billion

AZN ROE Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterly
1 y1 year+12.5%+5.0%
3 y3 years+4187.8%+573.9%
5 y5 years+88.6%+573.9%

AZN ROE Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs low
3 y3-yearat high+4187.8%at high+573.9%
5 y5-year-16.8%+4187.8%-37.8%+573.9%
alltimeall time-78.2%+4187.8%-69.4%+573.9%

AstraZeneca ROE History

DateAnnualQuarterly
Dec 2024
17.58%(+12.5%)
17.77%(+6.3%)
Sep 2024
-
16.71%(-0.9%)
Jun 2024
-
16.87%(-0.3%)
Mar 2024
-
16.92%(+6.1%)
Dec 2023
15.63%(+81.5%)
15.95%(-1.2%)
Sep 2023
-
16.14%(-5.0%)
Jun 2023
-
16.99%(+30.3%)
Mar 2023
-
13.04%(+45.9%)
Dec 2022
8.61%(+2000.0%)
8.94%(+63.7%)
Sep 2022
-
5.46%(-245.6%)
Jun 2022
-
-3.75%(+2.7%)
Mar 2022
-
-3.65%(-911.1%)
Dec 2021
0.41%(-98.1%)
0.45%(-93.9%)
Sep 2021
-
7.41%(-71.3%)
Jun 2021
-
25.81%(-9.7%)
Mar 2021
-
28.58%(+24.7%)
Dec 2020
21.14%(+126.8%)
22.92%(+24.4%)
Sep 2020
-
18.43%(+18.8%)
Jun 2020
-
15.52%(+37.8%)
Mar 2020
-
11.26%(+17.0%)
Dec 2019
9.32%(-33.7%)
9.62%(-36.0%)
Sep 2019
-
15.04%(-5.2%)
Jun 2019
-
15.87%(-9.8%)
Mar 2019
-
17.59%(+19.3%)
Dec 2018
14.05%(-22.0%)
14.75%(-9.3%)
Sep 2018
-
16.26%(-7.2%)
Jun 2018
-
17.53%(-3.9%)
Mar 2018
-
18.24%(-4.1%)
Dec 2017
18.02%(-9.4%)
19.01%(-17.1%)
Sep 2017
-
22.93%(-8.6%)
Jun 2017
-
25.08%(+16.0%)
Mar 2017
-
21.62%(+1.5%)
Dec 2016
19.89%(+34.3%)
21.30%(+43.1%)
Sep 2016
-
14.88%(+15.5%)
Jun 2016
-
12.88%(-22.6%)
Mar 2016
-
16.64%(+6.9%)
Dec 2015
14.81%(+157.6%)
15.56%(+70.2%)
Sep 2015
-
9.14%(+50.8%)
Jun 2015
-
6.06%(-4.7%)
Mar 2015
-
6.36%(+10.2%)
Dec 2014
5.75%(-46.9%)
5.77%(+24.1%)
Sep 2014
-
4.65%(-47.8%)
Jun 2014
-
8.90%(-0.9%)
Mar 2014
-
8.98%(-18.1%)
Dec 2013
10.83%(-58.9%)
10.97%(-44.7%)
Sep 2013
-
19.85%(-6.5%)
Jun 2013
-
21.22%(-15.0%)
Mar 2013
-
24.97%(-9.1%)
Dec 2012
26.32%(-37.8%)
27.46%(+1.6%)
Sep 2012
-
27.02%(-23.2%)
Jun 2012
-
35.18%(-5.7%)
Mar 2012
-
37.32%(-11.6%)
Dec 2011
42.31%(+16.2%)
42.24%(-2.9%)
Sep 2011
-
43.52%(+21.5%)
Jun 2011
-
35.81%(-2.5%)
Mar 2011
-
36.72%(+0.0%)
Dec 2010
36.41%(-10.7%)
36.71%(-2.7%)
Sep 2010
-
37.72%(-10.5%)
Jun 2010
-
42.14%(-2.1%)
Mar 2010
-
43.03%(+2.9%)
Dec 2009
40.79%(+3.6%)
41.83%(-1.1%)
Sep 2009
-
42.29%(+1.4%)
Jun 2009
-
41.72%(-2.5%)
Mar 2009
-
42.80%(+9.7%)
DateAnnualQuarterly
Dec 2008
39.39%(+6.8%)
39.02%(-2.0%)
Sep 2008
-
39.81%(+5.0%)
Jun 2008
-
37.92%(+0.7%)
Mar 2008
-
37.67%(-0.3%)
Dec 2007
36.89%(-11.2%)
37.77%(-3.1%)
Sep 2007
-
38.96%(-3.7%)
Jun 2007
-
40.47%(-2.2%)
Mar 2007
-
41.39%(+1.8%)
Dec 2006
41.52%(+24.3%)
40.66%(+0.7%)
Sep 2006
-
40.37%(+4.9%)
Jun 2006
-
38.50%(+5.5%)
Mar 2006
-
36.49%(+6.7%)
Dec 2005
33.39%(+26.5%)
34.19%(+6.4%)
Sep 2005
-
32.13%(+1.2%)
Jun 2005
-
31.74%(+8.5%)
Mar 2005
-
29.24%(+5.9%)
Dec 2004
26.40%(+6.9%)
27.60%(+7.5%)
Sep 2004
-
25.68%(+10.0%)
Jun 2004
-
23.35%(+3.9%)
Mar 2004
-
22.47%(-6.3%)
Dec 2003
24.69%(-9.2%)
23.98%(+3.8%)
Sep 2003
-
23.11%(+0.5%)
Jun 2003
-
22.99%(-7.5%)
Mar 2003
-
24.86%(-5.3%)
Dec 2002
27.20%(-12.1%)
26.26%(-13.1%)
Sep 2002
-
30.22%(-5.1%)
Jun 2002
-
31.83%(-0.4%)
Mar 2002
-
31.95%(+4.0%)
Dec 2001
30.94%(+21.1%)
30.73%(+11.4%)
Sep 2001
-
27.59%(+3.6%)
Jun 2001
-
26.62%(+0.3%)
Mar 2001
-
26.55%(+6.4%)
Dec 2000
25.55%(+138.3%)
24.95%(+46.2%)
Sep 2000
-
17.06%(+11.0%)
Jun 2000
-
15.37%(+19.6%)
Mar 2000
-
12.85%(+9.3%)
Dec 1999
10.72%(-70.0%)
11.76%(-66.6%)
Sep 1999
-
35.20%(-12.3%)
Jun 1999
-
40.15%(+0.3%)
Mar 1999
-
40.02%(-31.0%)
Dec 1998
35.75%(+7.9%)
58.04%(+35.0%)
Sep 1998
-
42.99%(-11.4%)
Jun 1998
-
48.53%(+27.9%)
Mar 1998
-
37.95%(-10.0%)
Dec 1997
33.13%(+0.8%)
42.15%(-12.1%)
Sep 1997
-
47.95%(+3.7%)
Jun 1997
-
46.24%(+3.7%)
Mar 1997
-
44.59%(-11.4%)
Dec 1996
32.88%(+82.5%)
50.34%(+46.7%)
Sep 1996
-
34.31%(+11.6%)
Jun 1996
-
30.73%(+6.8%)
Mar 1996
-
28.77%(+1.6%)
Dec 1995
18.02%(-34.3%)
28.32%(-20.8%)
Sep 1995
-
35.76%(-6.5%)
Jun 1995
-
38.23%(-9.9%)
Mar 1995
-
42.44%(+7.3%)
Dec 1994
27.44%(-46.3%)
39.56%(+4.7%)
Sep 1994
-
37.78%(+4.7%)
Jun 1994
-
36.09%(+24.7%)
Mar 1994
-
28.94%(+0.7%)
Dec 1993
51.13%(+129.0%)
28.75%
Dec 1992
22.33%(-72.3%)
-
Dec 1991
80.71%(+7.6%)
-
Dec 1990
75.00%
-

FAQ

  • What is AstraZeneca annual return on equity?
  • What is the all time high annual ROE for AstraZeneca?
  • What is AstraZeneca annual ROE year-on-year change?
  • What is AstraZeneca quarterly return on equity?
  • What is the all time high quarterly ROE for AstraZeneca?
  • What is AstraZeneca quarterly ROE year-on-year change?

What is AstraZeneca annual return on equity?

The current annual ROE of AZN is 17.58%

What is the all time high annual ROE for AstraZeneca?

AstraZeneca all-time high annual return on equity is 80.71%

What is AstraZeneca annual ROE year-on-year change?

Over the past year, AZN annual return on equity has changed by +1.95% (+12.48%)

What is AstraZeneca quarterly return on equity?

The current quarterly ROE of AZN is 17.77%

What is the all time high quarterly ROE for AstraZeneca?

AstraZeneca all-time high quarterly return on equity is 58.04%

What is AstraZeneca quarterly ROE year-on-year change?

Over the past year, AZN quarterly return on equity has changed by +0.85% (+5.02%)